| Date | Title | Description |
| 24.07.2026 | Dimension Launches $800 Million Fund To Invest Across Science And Compute | Dimension announced the launch of Dimension III, an $800 million fund dedicated to investing alongside entrepreneurs working across the frontiers of science and compute. With the new fund in place, the firm now manages a total of $1.65 bill... |
| 27.03.2026 | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Fri, Mar 27, 2026 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual Ge... |
| 23.03.2026 | Nathan Benaich's Air Street raises $232M Fund III, becoming Europe’s largest solo GP venture firm | Air Street Capital, founded by Nathan Benaich, has raised $232M for Fund III — making it the largest solo GP venture fund in Europe.
The fund invests in AI-first companies in North America and Europe. The firm will lead early-stage rounds w... |
| 06.01.2026 | Enveda inflammatory bowel disease drug candidate cleared for trial | Getting your Trinity Audio player ready...
Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, was recently cleared by the U.S. Food and Drug Administration to begin clinical trials ... |
| 05.09.2025 | Enveda raises another $150M, claims unicorn status | Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently closed a $150 million Series D funding round led by Premji Invest.
Subscribe to continue reading this article.
Already su... |
| 04.09.2025 | Enveda Raises $150M in Series D Funding | Enveda, a Boulder, CO-based clinical-stage biotech company, raised $150M in Series D funding.
The round was led by Premji Invest with participation from new and existing investors Baillie Gifford, Kinnevik, Lingotto Investment Management, P... |
| 04.09.2025 | NYSE Content Advisory: Pre-Market Update + Biotech Enveda raises $150 million to reach unicorn status | NEW YORK, Sept. 4, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Kristen Sch... |
| 14.01.2025 | Business | Jason Kim named CFO at Boulder’s Enveda | Jason Kim has been appointed chief financial officer at Enveda Biosciences, a biotechnology company using artificial intelligence to translate life’s chemistry into new medicines.
Subscribe to continue reading this article. Already subscrib... |
| 21.11.2024 | Enveda Biosciences raises $130M to advance AI-driven drug discovery from natural compounds
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our m... | Enveda Biosciences Inc., a biotechnology company that leverages artificial intelligence to develop new medicines, announced today that it has raised $130 million in new funding to deliver clinical catalysts across multiple programs with str... |
| 19.06.2024 | Enveda Biosciences: $55 Million Closed To Use AI For Translating Nature Into New Medicines | Enveda Biosciences, a biotechnology company that utilizes AI to translate nature into new medicines, announced a new funding round of $55 million to add to its $119 million combined Series B and B1. The new investors, Premji Invest, Lingott... |
| 17.06.2024 | Enveda Biosciences: Revolutionizing Drug Discovery Through the Power of AI | Enveda Biosciences, a dynamic biotechnology company hailing from the vibrant city of Boulder, Colorado, is making significant strides in the field of drug discovery by harnessing the transformative potential of artificial intelligence (AI).... |
| 16.06.2024 | Enveda Biosciences Raises $55M in Funding | Enveda Biosciences, a Boulder, CO-based biotechnology company using AI to translate nature into new medicines, raised a new financing round of $55m to add to its $119m combined Series B and B1.
New investors Premji Invest, Lingotto Investme... |
| 14.06.2024 | Enveda raises $55M to accelerate drug discovery with AI
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mission to provide free, deep, and r... | Enveda Biosciences Inc., a startup using artificial intelligence to develop new medicines, today announced that it has raised $55 million in funding to support its research.
Microsoft Corp. was among the more than half dozen investors that ... |
| 05.09.2023 | How Today’s Most Innovative Investors Are Shaking Up Venture Capital | Mariam Naficy, founder of Heretic Ventures (Photo by JP Yim/Getty Images for Tonic.xyz)Getty Images for Tonic.xyz |
| 25.04.2023 | Business
Business | Enveda Biosciences adds $51M to oversized Series B raise | BOULDER — Enveda Therapeutics Inc., the Boulder-based company that does business as Enveda Biosciences, recently added $51 million in equity investment to its December 2022 Series B round, bringing the fundraising total for the now-closed r... |
| 25.04.2023 | Enveda Biosciences Raises $51M in Series B1 | Enveda Biosciences, a Boulder, CO-based drug discovery and development company, raised an additional $51m in Series B1 equity financing.
Kinnevik led the Series B1 round, which also included participation by new investor Henry R. Kravis, th... |
| 27.12.2022 | Business
Business | Boulder’s Enveda Biosciences raises $68M | Boulder’s Enveda Therapeutics Inc. has raised $68 million in a combined debt and equity fundraising round and is on track to unveil several clinical treatment candidates in the new year.
The company, which does business as Enveda Bioscience... |
| 22.12.2022 | Business
Business | Boulder’s Enveda Biosciences raises $68M | BOULDER — Enveda Therapeutics Inc. has raised $68 million in a combined debt and equity fundraising round and is on track to unveil several clinical treatment candidates in the new year.
The company, which does business as Enveda Bioscience... |
| 21.12.2022 | Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing | Dimension led the round with multiple new institutional investors and significant participation from current investors; Silicon Valley Bank provided the debt facility
Company on track to declare multiple clinical candidates in 2023
BOULDER,... |
| 21.12.2022 | Enveda Biosciences Closes $68 Million Series B |
BOULDER, CO, Enveda Biosciences announced that it has closed a $68-million Series B round.
>> Click here for more funding data on Enveda Biosciences
>> To export Enveda Biosciences funding data to PDF and Excel, click here
... |
| 23.06.2021 | Enveda Biosciences Raises $51M in Series A Financing | Enveda Biosciences, a Boulder, Colo.-based biotechnology company leveraging nature’s chemistry to develop next-gen small molecule therapeutics, raised $51M in Series A funding.
The round was led by Lux Capital, with participation from Two S... |
| 23.06.2021 | Daily funding roundup - June 22nd, 2021 | Gloat raised $57M; Sporttrade landed $36M; Majority secured $19M, Coinme picks up $10M
G2: G2 is a Chicago-based software marketplace that features peer reviews that help simplify the buying process. G2 raised $157 million in Series D fundi... |
| 22.06.2021 | Boulder’s Enveda raises $51M Series A round | Enveda Therapeutics Inc. has closed a $51-million Series A fundraising round led by Lux Capital.
The company, which does business as Enveda Biosciences, is using artificial intelligence to identify potential therapeutics that occur in natur... |
| 22.06.2021 | Lux Capital Leads $51 Million Financing in Biotech Startup Enveda | Lux Capital has led a $51 million venture-capital financing in Enveda Biosciences Inc., a biotechnology startup led by an entrepreneur who previously helped build another successful life-sciences company in Lux’s portfolio.
Enveda founder a... |
| 22.06.2021 | Enveda Biosciences : Closes $51M Series A Financing Led by Lux Capital | Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced an oversubscribed $51M Series A funding round. The financing was led by Lux Capi... |
| 29.04.2021 | Slone Partners Places Sotirios Karathanasis as Chief Science Officer at Enveda Biosciences | “Dr. Karathanasis is a highly accomplished and respected scientist, researcher, and innovator with broad drug discovery and development experience whose intellect and insights will advance Enveda’s impressive drug discovery portfolio,” said... |
| 27.12.2020 | Enveda Biosciences Raises $4.9 Million To Engineer Drugs From Nature | Enveda Biosciences recently announced that it raised a seed round of funding of $4.9 million led by True Ventures. These are the details.
Enveda Biosciences recently announced that it raised a seed round of funding of $4.9 million led by Tr... |
| 16.12.2020 | Exclusive: Enveda Biosciences Announces $4.9M Seed To Create Medicinal Plant Database | 16 Shares Email Facebook Twitter LinkedIn
Enveda Biosciences has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biological data from medicinal plants.”
Subscri... |
| 16.12.2020 | Exclusive: Enveda Biosciences Announces $4.9M Seed To Create Medicinal Plant Database | 27 Shares Email Facebook Twitter LinkedIn
Enveda Biosciences has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biological data from medicinal plants.”
Subscri... |
| - | Enveda Biosciences | “Enveda” |
| - | Enveda Biosciences | “Transforming drug-discovery with the first high-resolution chemical map of the natural world.” |
| - | Enveda Biosciences: Drug Discovery Company Raises $119 Million | Enveda Biosciences announced that it had closed an additional $51 million equity financing to add to the $68 million Series B announced in December 2022. And Kinnevik led the Series B1 round, which also included participation by new investo... |
| - | Enveda Biosciences | “Enveda Biosciences | Plant-Powered Drug Discovery” |
